drugset / Trial / NCT00920153

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

NCT00920153

Phase 3 Terminated 442 enrolled French Innovative Leukemia Organisation
RandomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations may kill more cancer cells. It is not yet know which treatment regimen is more effective in treating Hodgkin lymphoma. PURPOSE: This phase III trial is studying three different therapy regimens to compare how well they work in treating patients with previously untreated Hodgkin lymphoma.

Timeline

Start
2008-05
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown Intravenous
Subject Cisplatin Other / unclassified Intravenous
Subject Cytarabine Small molecule Intravenous
Subject Dacarbazine Small molecule Intravenous
Subject Dexamethasone Small molecule Oral
Subject Doxorubicin Other / unclassified Intravenous
Subject Etoposide Small molecule Intravenous
Subject Gemcitabine Small molecule Intravenous
Subject Ifosfamide Small molecule Intravenous
Subject Melphalan Small molecule Intravenous
Subject Methylprednisolone Other / unclassified Intravenous
Subject Mitoguazone Small molecule Intravenous
Subject Vincristine Small molecule Intravenous
Subject Vindesine Small molecule Intravenous
Subject Vinorelbine Small molecule Intravenous
Subject carmustine Small molecule Intravenous

Indications